Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEGN5I)

• Drug Name: HMPL-689 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Lymphoma	2A80-2A86	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 118981804
  TTD Drug ID: DMEGN5I

Molecule-Related Drug Atlas

Drug(s) Targeting PI3-kinase delta (PIK3CD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BAY 80-6946	DMLOS5R	Follicular lymphoma	2A80	Approved	[3]
Idelalisib	DM602WT	Chronic lymphocytic leukaemia	2A82.0	Approved	[4]
Umbralisib	DMYRBO1	Follicular lymphoma	2A80	Approved	[5]
IPI-145	DMWA24P	Follicular lymphoma	2A80	Approved	[6]
Leniolisib	DMWAD93	Stomach cancer	2B72	Approved	[7]
Buparlisib	DM1WEHC	Breast cancer	2C60-2C65	Phase 3	[8]
INCB50465	DMZJP2T	Diffuse large B-cell lymphoma	2A81	Phase 2	[9]
ME-401	DMK0UOY	Follicular lymphoma	2A80	Phase 2	[9]
RP6530	DMYILGK	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[9]
Parsaclisib	DMYBIFS	Follicular lymphoma	2A80	Phase 2	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
PI3-kinase delta (PIK3CD)	TTGBPJE	PK3CD_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03786926) Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Hutchison MediPharma.
• [3] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [4] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [6] PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74.
• [7] Effective "activated PI3K syndrome"-targeted therapy with the PI3K inhibitor leniolisib. Blood. 2017 Nov 23;130(21):2307-2316.
• [8] Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Parsaclisib, a potent and highly selective PI3K inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019 Apr 18;133(16):1742-1752.